Abstract
The spectrum of gut microbiome composition is readily but controversially distilled into a handful of community types. In this issue of <i>Cell Host & Microbe</i>, Lee et al. (2021) find that matching pre-existing community types (and associated molecular biomarkers) to the class of immune biologic therapy in inflammatory bowel disease may double the treatment response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
